Clinical trials: Neuroendocrine Tumor Metastatic
Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7
Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma
This phase I/II trial studies how well genetically modified therapeutic autologous lymphocytes (patient's own white blood cells) followed by aldesleukin work in treating patients with stage III melanoma or melanoma that has…
- Conditions
- Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
- Trial name
- NCT01740557
- Testing
- Aldesleukin, CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes, Cyclophosphamide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma
Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone
The purpose of this study is to determine the maximum tolerated dose and characterize the safety profile of durvalumab (MEDI4736) in combination with dabrafenib and trametinib or with trametinib alone in participants with…
- Trial name
- NCT02027961
- Testing
- Durvalumab, Dabrafenib, Trametinib
- Where
- 11 sites in United States, Canada and 2 more
- Volunteers
- 68 people
- Sponsor
- MedImmune LLC
Melanoma, Skin Cancer
The Aim of This Study is to Demonstrat That Vacuum-assisted Closure Versus Conventional Wound Closure Enables to Diminish Local Complications After Lymph Node Dissection in Patients With Metastatic Skin Tumors
In this study, we compared a negative pressure wound therapy, versus a conventional dressing in order to evaluate the most efficient wound therapy closure after axillary and inguinal lymph nodes dissections in the management of…
- Conditions
- Melanoma, Skin Cancer, Epidermoid Carcinoma, Neuroendocrine Carcinoma
- Trial name
- NCT04583605
- Testing
- PREVENA
- Where
- France
- Volunteers
- 90 people
- Sponsor
- Central Hospital, Nancy, France
Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
A Phase 1/2, open label, multi-center study to evaluate the safety, efficacy and tolerability of alomfilimab as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies…
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Esophageal Cancer
- Trial name
- NCT03829501
- Testing
- Alomfilimab, Atezolizumab
- Where
- 22 sites in United States, Hungary and 4 more
- Volunteers
- 222 people
- Sponsor
- Kymab Limited
Melanoma
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma
The purpose of this study is to investigate the safety, immunogenicity and clinical activity of GSK2241658A antigen-specific cancer immunotherapeutic (ASCI) for the treatment of patients with non-operable and progressing…
- Trial name
- NCT01213472
- Testing
- GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic (ASCI)
- Where
- 24 sites in Australia, Austria and 6 more
- Volunteers
- 33 people
- Sponsor
- GlaxoSmithKline
Melanoma (Skin)
Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of perifosine in treating patients who have metastatic or…
- Trial name
- NCT00053781
- Testing
- perifosine
- Where
- 6 sites in Canada
- Volunteers
- 18 people
- Sponsor
- NCIC Clinical Trials Group
Non Functioning Pancreatic Endocrine Tumor
Diagnostic Accuracy of Preoperative Diagnostic Procedure in the Assessment of Lymph Node Metastases by NF-PanNENs
Pancreatic Neuroendocrine Neoplasms (PanNEN) are a heterogeneous group of neoplasms that arise from the endocrine cells of the pancreatic gland.
- Trial name
- NCT03918759
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- IRCCS San Raffaele
Metastatic Melanoma
Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma
This Phase II clinical study is an open-label, multicenter study of L19IL2 in combination with Dacarbazine in patients with metastatic melanoma.
- Trial name
- NCT01055522
- Testing
- Arm 1: L19IL2 + Dacarbazine, Arm 3: Dacarbazine, ARM 2: L19IL2 + Dacarbazine
- Where
- 10 sites in Austria, Germany and 2 more
- Volunteers
- 102 people
- Sponsor
- Philogen S.p.A.
Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
This phase II trial studies how well pazopanib hydrochloride works in treating patients with advanced neuroendocrine cancer. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for…
- Conditions
- Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Multiple Endocrine Neoplasia Type 1
- Trial name
- NCT00454363
- Testing
- Laboratory Biomarker Analysis, Pazopanib Hydrochloride, Pharmacological Study
- Where
- 3 sites in United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer, Cervical Cancer
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived engeneered T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens…
- Conditions
- Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma
- Trial name
- NCT05973487
- Testing
- TSC-204-A0201, TSC-204-C0702, TSC-200-A0201
- Where
- 21 sites in United States
- Volunteers
- 840 people
- Sponsor
- TScan Therapeutics, Inc.
Neoplasm Metastasis, Thyroid Neoplasm
Cryoablation of Bone Metastases From Endocrine Tumors
This study will evaluate the clinical response and safety of cone beam computed-tomography guided percutaneous cryoablation in bone metastases from thyroid, adrenal and neuroendocrine tumors in 30 patients.
- Conditions
- Neoplasm Metastasis, Thyroid Neoplasm, Pheochromocytoma, Adrenal Neoplasm
- Trial name
- NCT03986593
- Testing
- cryoablation
- Where
- Brazil
- Volunteers
- 17 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases
This early phase I trial tests the use of a radioactive tracer (a drug that is visible during an imaging test) known as 18F-FMAU, for imaging with positron emission tomography/computed tomography (PET/CT) in patients with brain…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Glioma, Malignant Brain Neoplasm
- Trial name
- NCT04752267
- Testing
- Computed Tomography, 18F-FMAU, Multiparametric Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Southern California
Malignant Melanoma
A Study of RO5185426 in Patients With Metastatic Melanoma
This is an open-label, non-comparative, multicenter, expanded access study of RO5185426 in patients who have received prior systemic therapy for metastatic melanoma and who have no other satisfactory treatment options.
- Trial name
- NCT01248936
- Testing
- RO5185426
- Where
- 28 sites in United States
- Volunteers
- 374 people
- Sponsor
- Hoffmann-La Roche
Malignant Melanoma, Liver Metastases
Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma
This study is the first to explore the efficacy and safety of recombinant human adenovirus type 5 injection combined with PD-1 monoclonal antibody and nab-paclitaxel in the treatment of patients with liver metastases of melanoma…
- Trial name
- NCT05664139
- Testing
- Recombinant Human Adenovirus Type 5 Injection,Camrelizumab,Nab-paclitaxel
- Volunteers
- 30 people
- Sponsor
- Fujian Cancer Hospital
Metastatic Melanoma, Liver Metastases
Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
This study is being done to see if combining HEPZATO KIT™ with nivolumab and relatlimab (Opdualag™) in patients with metastatic melanoma with liver metastasis is safe, tolerable, and will have a synergistic effect leading to…
- Trial name
- NCT07281924
- Testing
- Nivolumab and Relatlimab, Melphalan
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Wisconsin, Madison
Melanoma
BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma
The purpose of the study is to assess the safety and efficacy of BGB324 given together with standard treatment, pembrolizumab or dabrafenib and trametinib, compared to standard treatment alone,
- Trial name
- NCT02872259
- Testing
- BGB324+pembrolizumab, BGB324+dabrafenib and trametinib, pembrolizumab
- Where
- 5 sites in Norway
- Volunteers
- 74 people
- Sponsor
- Haukeland University Hospital
Neuroendocrine Tumors
Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors
This is a prospective, international, multi-center, open label, stratified, exploratory phase II study evaluating the efficacy and safety of lenvatinib in patients with advanced/metastatic, neuroendocrine tumors of the pancreas…
- Trial name
- TALENT (NCT02678780)
- Testing
- Lenvatinib
- Where
- 22 sites in Austria, Italy and 2 more
- Volunteers
- 123 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Metastatic Uveal Melanoma, Metastatic Cutaneous Melanoma
Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases
The purpose of this study is to evaluate the feasibility, safety and tolerability of treatment with autologous tumor infiltrating lymphocytes (TIL) administered via hepatic arterial infusion in patients with liver metastases…
- Trial name
- HAITILS (NCT04812470)
- Testing
- Autologous Tumor Infiltrating Lymphocytes, Melphalan, Interleukin-2
- Where
- Sweden
- Volunteers
- 8 people
- Sponsor
- Vastra Gotaland Region
BRAF Mutant Metastatic Melanoma
BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma
This is a phase 1/2 clinical trial with the goal of determining whether the addition of the investigational agent BKM120 to vemurafenib will lead to improved 6-month progression-free survival in patients with BRAFV600E/K mutant…
- Trial name
- NCT01512251
- Testing
- BKM120 Combined with Vemurafenib (PLX4032)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of California, San Francisco
Advanced Cancer, Metastatic Cancer
Phase I Intratumoral Pbi-shRNA STMN1 LP in Advanced and/or Metastatic Cancer
This is a Phase I safety trial of bifunctional shRNA-STMN1 (pbi-shRNA™STMN1) BIV (bilamellar invaginated vesicle) lipoplex (LP), pbi-shRNA™ STMN1 LP administered by a single intratumoral (IT) injection.
- Conditions
- Advanced Cancer, Metastatic Cancer, Solid Tumors
- Trial name
- STMN1-LP (NCT01505153)
- Testing
- pbi-shRNA STMN1 LP
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Gradalis, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.